A Phase II study conducted by AltheRx Pharmaceuticals has revealed that its Solabegron drug showed improvements in symptoms of overactive bladder (OAB) compared to placebo.

Solabegron is a beta3-adrenoceptor agonist with high affinity and selectivity that is in late stage clinical development for the treatment of OAB and irritable bowel syndrome (IBS).

The Phase II multi-centre randomised double-blind placebo-controlled parallel group study compared 50mg and 125mg dosage strengths of Solabegron to placebo in 258 women with moderate to severe OAB symptoms.

Patients treated with Solabegron 125mg showed a 65.6% reduction from baseline in incontinence episodes and 21% improvement in adjusted mean difference from placebo.

Solabegron-treated subjects also reported a considerable reduction in the frequency of urination and increase in the volume of urine voided over placebo.

The study results also demonstrated that Solabegron 125mg was safe and well-tolerated with no notable changes in any cardiovascular parameters measured by 24-hour ambulatory blood pressure, clinical chemistry, haematology, or ECG parameters.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Roger Dmochowski, Professor at the Department of Urology, Vanderbilt University Medical Center, said, "With a novel mechanism of action, Solabegron may offer an important new treatment modality in OAB that may help us improve patients’ symptoms and quality of life.

"Results of future Phase III clinical trials are awaited to further assess the therapeutic benefits of this compound," Dmochowski added.

AltheRx plans to begin patient enrolment in the Phase IIb/III study of Solabegron in OAB later this year.

Overactive bladder is a common bladder control problem defined by a set of symptoms including urgency, with or without urge incontinence, usually with frequency and nocturia.

AltheRx Pharmaceuticals is a privately held, clinical development company focused on advancing best-in-class compounds through clinical development and the creation of partnerships with biopharmaceutical companies for commercialisation.